Marker vaccine potential of a foot-and-mouth disease virus with a partial VP1 G-H loop deletion.
Previous work in cattle and pigs demonstrated that protection against foot-and-mouth disease (FMD) could be achieved following vaccination with chimeric foot-and-mouth disease virus (FMDV) vaccines, in which the VP1 G-H loop had been substituted with that from another serotype. This indicated that the VP1 G-H loop may not be essential for the protection of natural hosts against FMDV. If this could be substantiated there would be potential to develop FMD marker vaccines, characterised by the absence of this region. Here, we investigate the serological responses to vaccination with a virus with a partial VP1 G-H loop deletion in order to determine the likelihood of achieving protection and the potential of this virus as a marker vaccine. Inactivated, oil adjuvanted, vaccines, consisting of chemically inactivated virus with or without a partially deleted VP1 G-H loop, were used to immunise cattle. Serum was collected on days 0, 7, 14 and 21 and antibody titres calculated using the virus neutralisation test (VNT) to estimate the likelihood of protection. We predict a good likelihood that cattle vaccinated with a vaccine characterised by a partial VP1 G-H loop would be protected against challenge with the same virus containing the VP1 G-H loop. We also present evidence on the potential of such a construct to act as a marker vaccine, when used in conjunction with a novel serological test.
Fowler
V L
VL
Institute for Animal Health, Pirbright Laboratory, Ash Road, Surrey, GU24 0NF, UK. veronica.fowler@bbsrc.ac.uk
Knowles
N J
NJ
Paton
D J
DJ
Barnett
P V
PV
D000276:Adjuvants, Immunologic / Q000008:administration & dosage; D000818:Animals; D057134:Antibodies, Neutralizing / Q000097:blood; D000914:Antibodies, Viral / Q000097:blood; D036022:Capsid Proteins / Q000235:genetics / Q000276:immunology*; D002417:Cattle; D002418:Cattle Diseases / Q000517:prevention & control; D005536:Foot-and-Mouth Disease / Q000175:diagnosis / Q000517:prevention & control; D029544:Foot-and-Mouth Disease Virus / Q000235:genetics / Q000276:immunology*; D009500:Neutralization Tests; D009821:Oils / Q000008:administration & dosage; D017384:Sequence Deletion; D015164:Vaccines, Inactivated / Q000235:genetics / Q000276:immunology; D022581:Vaccines, Marker / Q000235:genetics / Q000276:immunology; D014765:Viral Vaccines / Q000235:genetics / Q000276:immunology*
D000276:Adjuvants, Immunologic; D057134:Antibodies, Neutralizing; D000914:Antibodies, Viral; D036022:Capsid Proteins; D009821:Oils; C442501:VP1 protein, Foot-and-mouth disease virus; D015164:Vaccines, Inactivated; D022581:Vaccines, Marker; D014765:Viral Vaccines